TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB40961

Peptide_Name

Peptide-327

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0 dbACP

Sequence_Type

standard

Has_Modification No

Description A 9-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and dbACP, with an available 3D structural model.

Sequence

EFLDCFQKF

FASTA

>TPDB40961|Anticancer|length=9
EFLDCFQKF

Formula C56H77N11O15S1

Absent Amino Acids ARNGHIMPSTWYV

Common Amino Acids F

Mass 1176.35

PI 4.07

Basic Residues 1

Acidic Residues 2

Hydrophobic Residues 4

Net Charge -1

Boman Index 0.63

Hydrophobicity 0.033

Aliphatic Index 43.33

Half Life

Mammalian: 1 hour Yeast: 30 min E.coli: >10 hour

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 2

number

0

A

0

R

0

N

1

D

1

C

1

E

1

Q

0

G

0

H

0

I

1

L

1

K

0

M

3

F

0

P

0

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 1 C: 1 E: 1 Q: 1 G: 0 H: 0 I: 0 L: 1 K: 1 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

9

Formula

C56H77N11O15S1

Mass

1176.35

PI

4.07

Net Charge

-1

Boman Index

0.63

Hydrophobicity

0.033

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

EGFR binding region for Eps8 (aa 289–362)

Evidence 1 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 119.84 ± 16.01 µM

Detail Source Activity Anticancer

Activity Measurement 119.84

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 107.34 ± 11.87 µM

Detail Source Activity Anticancer

Activity Measurement 107.34

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 3 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 83.10 ± 1.41 µM

Detail Source Activity Anticancer

Activity Measurement 83.10

Target

Cancer Type Colon Cancer

Cell Line Colo-320

Tissue Affected Colon

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 4 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 96.00 ± 9.06 µM

Detail Source Activity Anticancer

Activity Measurement 96.00

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 5 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 102.35 ± 4.66 µM

Detail Source Activity Anticancer

Activity Measurement 102.35

Target

Cancer Type Colorectal Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 6 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 = 50.69 ± 1.58 µM

Detail Source Activity Anticancer

Activity Measurement 50.69

Target

Cancer Type Prostate Cancer

Cell Line PC-3/A24

Tissue Affected Prostate

Assay & Model

Assay CCK-8 assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018